1 (edited by KarenD Thu, 16 May 2013 14:39:42)

Topic: Some info from ONS congress

Hello everyone!

I am finally sitting down to say "Hi" to you all, and post a couple of things about ONS congress. 

The Oncology Nursing Society holds a congress, or conference yearly to discuss new developments in cancer care.  Of course there is ASCO which is the BIG global cancer conference, but the one I attended is nursing focused.

I am ever so grateful for being given the opportunity to represent our foundation, and to meet new people who can further our cause.

I also was so happy to meet a new advocate, Heidi.  She is absolutely WONDERFUL, warm, and caring. I hope to see her again sometime. smile

Anyhow, I spent the majority of my time looking through the poster presentations and was also able to attend a couple of sessions.

One interesting poster/presenter was one that I had seen last year at ASCO discussing Grade 3-4 FU toxicity.  The presenter was at ONS with new developments recently discovered.


The poster was titled:

"DPYD Gene Mutations Are More Prevalent in Patients Experiencing Grade 3-4-FU Toxicity"


The research was funded by Myriad Genetic Laboratories, Inc., Salt Lake City, UT.


The new research presented on the poster was  DPYD mutation prevalence in patients with elevated 5-FU Plasma Levels.

" The DPYD gene variants were identified in 7 of the 24 patients experiencing elevated 5-FU plasma levels".
"The E412E variant was observed at a frequency similar to that of the common high risk mutations".


So what this says to me is that, as we are all rapidly realizing, our genes play a huge part in how and why our bodies develop cancer.....or how our bodies will react to treatments for cancer.
Chemotherapy is moving towards targeted, gene based therapy.  Very individualized.

5-FU is a commonly given chemotherapy agent, and some of  you have received the oral form- Xeloda for treatment of CC.

To quote the poster " 5-FU in chemotherapy regimens remains widespread, yet DPYD gene testing utilization remains minimal.  Most testing occurs post-treatment in response to a severe toxicity rather than pre-treatment, which would allow for treatment adaptation to reduce toxicity risk".

Perhaps with this new research, patients prescribed Xeloda or 5-FU as part of their treatment plan will be tested prior to initiation of therapy.  This would in my opinion, greatly improve the quality of a person's life (less toxic side effects), and perhaps increase the chances that the treatment plan (chemotherapy regimen) will be maintained.



Another poster I saw was by a nurse researcher out of Korea.  It was a study done on foot reflexology and the decrease in dyspnea ( shortness of breath)  in cancer patients. 
What caught my eye was that one of the patients in the study had Cholangiocarcinoma.

I will have to track down the abstract for the poster as the phone I had taken a picture of it with crashed and it got lost! AHH!  But needless to say, I think it is exciting to see studies of CAM (complementary and Alternative Medicine)  implementation. 

As soon as I track down the abstract I will attempt to post it for everyone.   

I also bumped into two old colleagues of mine who are APRNs in Virginia.  I was able to pass along our information, and discuss our foundation (and our goals) with them.  I will be shipping our beautiful new newsletter and foundation packets out to their cancer center in Richmond.

-Karen

2 (edited by Lainy Thu, 16 May 2013 16:23:55)

Re: Some info from ONS congress

Karen, thank you so much. Lots to digest but so much to look forward with things moving upward and onward. Thank you very much for representing us you are just wonderful. It solidifies Percy's statements that new treatments are right around the corner. You are all awesome!

Teddy ~In our hearts forever~ATTITUDE is EVERYTHING
Any suggestion I offer is intended as friendly advice based solely on my own experience. Please consult your doctor for professional guidance.

Re: Some info from ONS congress

Thanks, Karen for your kindness in volunteering for the Cholangiocarcinoma Foundation.  It is people like you that make a difference to our patient community.
Hugs and thanks again,
Marion

THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER

Re: Some info from ONS congress

Many thanks for that and for all of your work Karen!!! Great stuff!!

Any advice or comments I give are based on personal experiences and knowledge and are my opinions only, they are not to be substituted for professional medical advice. Please seek professional advice from a qualified doctor or medical professional.

Re: Some info from ONS congress

Thank you, Karen!

Willow

Re: Some info from ONS congress

Karen, an oncology nurse and mother of two little children, has been a much needed addition to the foundation.  Karen, we appreciate your taking off the time from work and family, in order to further our presence at medical conferences and especially at nursing society conferences. 
Thank you, thank you, dear Karen, for all you do for us and the cholangocarcioma patient community at large.
Hugs,
Marion

THIS INFORMATION IS NOT INTENDED NOR IMPLIED TO BE A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER